Google NewsWhy Amplia Therapeutics (ASX:ATX) Is Drawing Fresh Buzz? - Kalkine
Why Amplia Therapeutics (ASX:ATX) Is Drawing Fresh Buzz? Kalkine
AMPLIA THERAPEUTICS ORDINARY (ATX) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASXAppendix 4G - Key to Corporate Governance Disclosures
other announcement
Preliminary Final Report and Annual Report YE 31 March 2026
other announcement
Amplia Launches First Stage of Pivotal Narmafotinib Trial
other announcement
Notice under Section 708A(5)(e) of the Corporations Act
other announcement
Amplia (ASX:ATX) Adds Ovarian Trial with ANZGOG After Narmafotinib Hits 35% Pancreatic Response Rate - Stocks Down Under
Amplia (ASX:ATX) Adds Ovarian Trial with ANZGOG After Narmafotinib Hits 35% Pancreatic Response Rate Stocks Down Under
ACCENT Trial Mature Data Presented at AACR Conference
other announcement
Amplia MD Responds to Questions Regarding AMPLICITY Trial
other announcement
Small CapsAmplia Therapeutics Halts Recruitment in AMPLICITY Trial
other announcement
Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth - simplywall.st
Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth simplywall.st
Amplia (ASX:ATX) Surges 80% After Rare Pancreatic Cancer Responses - Stocks Down Under
Amplia (ASX:ATX) Surges 80% After Rare Pancreatic Cancer Responses Stocks Down Under
KalkineIs Amplia Therapeutics (ASX:ATX) Advancing Cancer Trial Progress?
Highlights • Amplia reports key clinical milestone in pancreatic cancer program. • Narmafotinib responses contribute to ongoing trial development. • Clinical progress supports broader oncology research framework. Amplia Therapeutics advances pancreatic cancer research through clinical trial progress, highlighting healthcare sector activity within the ASX All Ordinaries framework. The biotechnology and healthcare sector plays a significant role in advancing medical research, drug ...
Amplia Reports Improved Responses & Survival in ACCENT trial
other announcement
Benefit of Narmafotinib in kRas-Mutated Cancer Models
other announcement
US Sites For AMPLICITY Pancreatic Cancer Trial Open
other announcement
ACCENT Data Presented at 2026 ASCO GI Cancer Symposium
other announcement
Amplia Enters 2nd Agreement with Drug Screening Co Next Bio
other announcement
Additional Confirmed Response Reported-Investor Presentation
other announcement
Positive Response from US FDA to Amplia's Type D Meeting
other announcement
Amplia Commences Trading on U.S. OTCQB Venture Market
other announcement
Amplia Receives R&D Tax Rebate Totalling $3.77 Million
other announcement
Amplia Therapeutics to Significantly Expand U.S. Presence
other announcement
ADDITIONAL RESPONSES IN ACCENT PANCREATIC CANCER TRIAL
other announcement
Patent Allowance for Key Narmafotinib Patent in US
other announcement
Change of Director's Interest Notice - Warwick Tong
director_dealing announcement
Change of Director's Interest Notice - Chris Burns
director_dealing announcement
Change of Director's Interest Notice - Robert Peach
director_dealing announcement
Change of Director's Interest Notice - Jane Bell
director_dealing announcement
FIRST PATIENT DOSED IN NEW PANCREATIC CANCER TRIAL
other announcement
NARMAFOTINIB ADOPTED AS NONPROPRIETARY DRUG NAME IN USA
other announcement
Notice under Section 708A(5)(e) of the Corporations Act
other announcement
AUSTRALIAN TRIAL SITES OPEN FOR NEW NARMAFOTINIB TRIAL
other announcement
Amplia Share Purchase Plan Raises $2.65 Million
capital_raise announcement
Presentation - Targeting Pancreatic Cancer and Beyond
other announcement